NeoGenomics (NASDAQ:NEO) Rating Increased to Hold at BidaskClub

NeoGenomics (NASDAQ:NEO) was upgraded by investment analysts at BidaskClub from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Friday, BidAskClub reports.

A number of other analysts also recently issued reports on NEO. William Blair reiterated an “outperform” rating on shares of NeoGenomics in a report on Tuesday, October 29th. ValuEngine upgraded shares of NeoGenomics from a “hold” rating to a “buy” rating in a report on Friday, November 1st. Zacks Investment Research upgraded shares of NeoGenomics from a “sell” rating to a “hold” rating in a report on Tuesday, November 5th. Leerink Swann set a $30.00 price target on shares of NeoGenomics and gave the company a “buy” rating in a report on Wednesday, July 31st. Finally, Raymond James lifted their price target on shares of NeoGenomics from $23.00 to $27.00 and gave the company an “outperform” rating in a report on Wednesday, July 31st. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. NeoGenomics currently has a consensus rating of “Buy” and a consensus price target of $25.00.

NEO stock traded up $0.59 on Friday, hitting $24.07. The company had a trading volume of 487,200 shares, compared to its average volume of 668,545. The company has a current ratio of 4.24, a quick ratio of 4.05 and a debt-to-equity ratio of 0.24. The stock has a market cap of $2.45 billion, a price-to-earnings ratio of 185.15 and a beta of 0.94. The stock’s 50-day simple moving average is $20.90 and its 200 day simple moving average is $22.61. NeoGenomics has a 12-month low of $11.05 and a 12-month high of $26.89.

NeoGenomics (NASDAQ:NEO) last announced its quarterly earnings results on Tuesday, October 29th. The medical research company reported $0.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.01. The company had revenue of $104.70 million for the quarter, compared to the consensus estimate of $99.38 million. NeoGenomics had a net margin of 0.55% and a return on equity of 4.60%. NeoGenomics’s revenue for the quarter was up 51.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.05 EPS. Research analysts forecast that NeoGenomics will post 0.19 earnings per share for the current year.

In other NeoGenomics news, Director Steven C. Jones sold 40,737 shares of NeoGenomics stock in a transaction on Friday, August 30th. The shares were sold at an average price of $25.02, for a total value of $1,019,239.74. Following the completion of the transaction, the director now directly owns 245,234 shares of the company’s stock, valued at approximately $6,135,754.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider George Cardoza sold 19,444 shares of NeoGenomics stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $23.15, for a total transaction of $450,128.60. Following the completion of the transaction, the insider now directly owns 345,275 shares of the company’s stock, valued at $7,993,116.25. The disclosure for this sale can be found here. Insiders sold a total of 382,843 shares of company stock valued at $9,272,947 over the last three months. Corporate insiders own 8.80% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. boosted its stake in shares of NeoGenomics by 8.0% during the 2nd quarter. BlackRock Inc. now owns 14,925,327 shares of the medical research company’s stock worth $327,462,000 after purchasing an additional 1,100,263 shares during the period. Vanguard Group Inc. boosted its stake in shares of NeoGenomics by 41.6% during the 2nd quarter. Vanguard Group Inc. now owns 8,173,714 shares of the medical research company’s stock worth $179,331,000 after purchasing an additional 2,401,227 shares during the period. Brown Advisory Inc. boosted its stake in shares of NeoGenomics by 0.3% during the 2nd quarter. Brown Advisory Inc. now owns 2,525,843 shares of the medical research company’s stock worth $55,417,000 after purchasing an additional 8,524 shares during the period. Emerald Advisers LLC boosted its stake in shares of NeoGenomics by 3.8% during the 2nd quarter. Emerald Advisers LLC now owns 1,951,061 shares of the medical research company’s stock worth $42,806,000 after purchasing an additional 72,160 shares during the period. Finally, Granite Investment Partners LLC boosted its stake in shares of NeoGenomics by 1.6% during the 2nd quarter. Granite Investment Partners LLC now owns 1,791,477 shares of the medical research company’s stock worth $39,305,000 after purchasing an additional 27,387 shares during the period. 84.48% of the stock is owned by hedge funds and other institutional investors.

About NeoGenomics

NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States; and laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company's laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories.

Featured Article: How Buying a Call Option Works

Analyst Recommendations for NeoGenomics (NASDAQ:NEO)

Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.